PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas

Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, Zhang J, Liu X, Xu W, Krepler C, Sproesser K, Xiao M, Miao B, Liu J, Song CD, Liu JY, Karakousis GC, Schuchter LM, Lu Y, Mills G, Cong Y, Chernoff J, Guo J, Boland GM, Sullivan RJ, Wei Z, Field J, Amaravadi RK, Flaherty KT, Herlyn M, Xu X, Guo W. Nature. 2017 Sep 27. doi: 10.1038/nature24040. [Epub ahead of print]


Almost all patients with metastatic melanoma who are treated with combination therapies eventually relapse. New research led by Wei Guo of the School of Arts and Sciences, Xiaowei Xu of the Perelman School of Medicine and Meenhard Herlyn of the Wistar Institute shows how to overcome acquired drug resistance.
Read the Penn Department of Communications news release.